22 citations
,
March 2000 in “Clinics in Dermatology” This study developed a method using HPLC with UV-DAD and ESI-MS detection to identify prohibited substances like minoxidil and hormones in cosmetic products advertised online for hair loss and skin conditions.
68 citations
,
April 2002 in “Journal of Alternative and Complementary Medicine” This study suggests that botanical 5AR inhibitors like Serenoa repens and β-sitosterol may improve symptoms of androgenetic alopecia, with 60% of treated subjects showing improvement compared to placebo.
This review concludes that the global literature supports the efficacy and safety of lipidosterolic extract of Serenoa repens in treating lower urinary tract symptoms, comparable to alpha-blockers and 5α-reductase inhibitors.
8 citations
,
October 2020 in “Pharmaceutics” This study explored using a chitosan oligomer coating for topical delivery of dutasteride-loaded nanostructured lipid carriers, aiming to reduce systemic exposure and cytotoxicity.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.
July 2026 in “International Journal of Drug Delivery Technology” This research reported that liposomal systems made from pig-derived skin lipids enhanced finasteride delivery to hair follicles for treating androgenetic alopecia, showing improved drug deposition, hair length, and growth compared to conventional finasteride forms in vitro.